Abbott Laboratories (ABT)
$
133.6
+0.38 (0.28%)
Key metrics
Financial statements
Free cash flow per share
3.8101
Market cap
233.9 Billion
Price to sales ratio
5.5239
Debt to equity
0.2713
Current ratio
1.7805
Income quality
0.6651
Average inventory
6.4 Billion
ROE
0.3076
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $10,834,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $16,419,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $11,697,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $7.64 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $133.60 appealing to a broad range of investors. With a large market capitalization of $232,442,624,000.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 6,352,350.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Abbott Laboratories stock to fluctuate between $99.71 (low) and $141.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-10, Abbott Laboratories's market cap is $232,442,624,000, based on 1,739,840,000 outstanding shares.
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Abbott Laboratories pays dividends. The current dividend yield is 2.15%, with a payout of $0.59 per share.
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
Revenue: $41,950,000,000 | EPS: $7.74 | Growth: 134.55%.
Visit https://www.abbott.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.
forbes.com
Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500's 6% rise. This strong performance is due to the company's solid quarterly results and positive future forecasts.
zacks.com
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
zacks.com
In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.
zacks.com
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
seekingalpha.com
Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segments offsets weakness in Diagnostics and China sales, showcasing resilience and adaptability. Management's focus on gross margin expansion, cost-saving initiatives, and shareholder-friendly policies like dividend increases support long-term value.
zacks.com
In the closing of the recent trading day, Abbott (ABT) stood at $133.67, denoting a -2.71% move from the preceding trading day.
zacks.com
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
seekingalpha.com
Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a collective 2025 growth rate of 5.19%, despite some downward earnings revisions. Seventeen Dividend Kings appear undervalued and offer long-term annualized expected returns of at least 10%, based on Dividend Yield Theory analysis.
See all news